Scott E. Monroe

No ORCID on file · 5 papers in corpus
nonrandomized-trial 1997
Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (Ganirelix) administered by intranasal spray
Fertility and sterility ·doi:10.1016/s0015-0282(97)80071-4

OBJECTIVE: To determine if the GnRH antagonist (GnRH-a) Ganirelix (Syntex Research, Palo Alto, CA), administered by intranasal (IN) spray to normal women, is absorbed into the systemic circulation and suppresses LH secretion. DESIGN: A sin…

other 1995
Effects of a gonadotropin-releasing hormone agonist on the calcium-parathyroid axis and bone turnover in women with endometriosis
American journal of obstetrics and gynecology ·doi:10.1016/0002-9378(95)90348-8

OBJECTIVE: Our purpose was to investigate the effects of nafarelin on bone turnover and mass (bone mineral density, in grams per square centimeter) in women with endometriosis. STUDY DESIGN: We monitored 22 young women with endometriosis d…

1987
Clinical Investigations of the Contraceptive and Therapeutic Potential of Nafarelin
·doi:10.1007/978-94-009-3229-6_17
1987
Treatment of Endometriosis by Nasal Administration of Nafarelin
·doi:10.1007/978-94-009-3229-6_22
other 1985
Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin)
Fertility and sterility ·doi:10.1016/s0015-0282(16)48970-3

Administration of superactive agonistic analogs of gonadotropin-releasing hormone (GnRH) has been shown to induce a paradoxic and reversible suppression of gonadotropins, resulting in suppressed gonadal steroid concentrations. Because there…